Telomir says preclinical Telomir-Zn study shows dose-dependent survival gain in Wilson’s disease model

Telomir

Telomir

TELO

0.00
  • Telomir Pharmaceuticals disclosed a new peer-reviewed preclinical study on Telomir-Zn in a Wilson’s disease model, with results already published in Advances in Redox Research.
  • The study showed dose-dependent survival gains alongside broad signs of disease improvement, including lower liver copper burden and better liver health signals.
  • The findings add external validation for Telomir-Zn’s biological activity in Wilson’s disease, a potential expansion path alongside its lead triple-negative breast cancer program, which received FDA IND clearance in April 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605200800ACCESSWRNAPR_____1168259) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.